Glenmark Windfall: Mutual Funds Beat Retail Hands Down

 

Mutual Funds Reap Windfall as Glenmark Soars on $2B AbbVie Deal

Mumbai, July 11, 2025: Glenmark Pharmaceuticals Ltd. witnessed a spectacular surge on the bourses today, locking firmly into the 10% upper circuit after announcing a landmark $2 billion licensing deal with US pharmaceutical giant AbbVie for its oncology drug candidate, ISB 2001. However, the biggest cheers are likely echoing in the halls of India's top mutual fund houses, who had placed significant, sustained bets on the company while retail investors steadily exited.

Also Read ChatGPT-Powered Challenger Takes Aim at Google Chrome

The deal, involving a substantial $700 million upfront payment and up to $1.2 billion in potential milestone payments, validates Glenmark's research and development (R&D) focus. Analysts highlight that if ISB 2001 succeeds commercially, the resulting royalty stream could potentially surpass Glenmark's current EBITDA. This prospect, investors say, could significantly de-risk the company's balance sheet and fundamentally "re-rate the innovation story" Glenmark has pursued for years.

Also Read  TCS Q1: Attrition Up, Net Headcount Grows

Institutional Conviction Pays Off, Retail Misses Out

Data reveals a stark divergence in investor behaviour leading up to this catalyst:

Mutual Funds (The Big Winners): Ownership soared from 9.1% in June 2023 to 14.6% by March 2025. This aggressive accumulation signaled strong institutional faith in Glenmark's pipeline, even as the broader market underestimated its R&D potential.

Retail Investors (The Missed Opportunity): Public shareholding declined significantly from 20.4% to 15.56% over the same period, indicating retail investors were reducing exposure just before the major upswing.

"Mutual funds just beat retail shareholders hands down... and the score wasn’t even close," the data starkly illustrates. Fund managers' belief that Glenmark's innovation pipeline was undervalued was decisively proven right by the AbbVie deal.

Also Read Smartworks IPO Opens GMP ₹32, Subscribed 0.04x

Key Institutional Beneficiaries

Several prominent fund houses reaped significant rewards from their strategic holdings:

HDFC Mutual Fund: Led the charge. Its Midcap Opportunities Fund held a massive 1.06 crore shares, with significant exposure also in its Manufacturing Fund (12 lakh shares) and Balanced Advantage Fund (8.85 lakh shares).

Other Major Holders: UTI Value Fund (9 lakh shares), Bandhan Small-cap Fund (8.62 lakh shares), and Aditya Birla Sun Life Midcap Fund (7.01 lakh shares).

Recent Aggressive Buyers: Mahindra Manulife Mutual Fund emerged as a top buyer in June, adding 8.45 lakh shares via its Multi Cap Fund and 3.6 lakh via its Small Cap Fund. Invesco India Mid Cap Fund also boosted its stake by nearly 20%, picking up 2.74 lakh shares.

Also Read Samsung’s New Foldables Boost Old Videos with Secret AI Tool

Marquee Names & Other Shareholders

Promoters maintained a controlling 46% stake.

Foreign Institutional Investors (FIIs) held steady around 23%, though activity was mixed (e.g., Smallcap World Fund trimmed its stake, while Norway’s Government Pension Fund Global held firm at 3.25%).

Marquee investors included Prashant Jain’s 3P India Equity Fund (~1%) and Ashish Dhawan (1.77% personally in March 2025, down from 2.55% in Sept 2024).

Also Read Nvidia Tops $4 Trillion AI Chip Giant Makes History

The immediate windfall for institutions is clear from today's circuit-breaking surge. However, the true long-term value hinges on the success of ISB 2001. If the drug gains approval and market traction, Glenmark stands to unlock a transformative revenue stream, vindicating the patient capital deployed by domestic mutual funds and potentially reshaping the company's financial future and market valuation. For retail investors who exited, it serves as a stark reminder of the potential rewards – and risks – of betting against institutional conviction in deep R&D pipelines.

Disclaimer: The content on PulseNext is for informational purposes only and not investment advice. Stock market investments carry risks, including loss of capital. Always do your own research or consult a financial advisor before investing.